Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 2/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.32 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.32 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 3/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.31 |
| ▸ | KMO | O15229 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16288137 | 0.85 | CYP2A6 (0.43) | CYP2A6NOS3NOS1NOS2LOXL2 | |
| SCHEMBL548410 | 0.64 | CYP2A6 (0.50) | CYP2A6NOS3NOS1NOS2PGR | |
| SCHEMBL827799 | 0.64 | CYP2A6 (1.00) | CYP2A6NOS3NOS1NOS2PGR | |
| SCHEMBL29968261 | 0.64 | CYP2A6 (1.00) | CYP2A6NOS3NOS1NOS2PGR | |
| SCHEMBL16289866 | 0.61 | CA1 (0.41) | CYP2A6PGRLOXL2IMPDH2IMPDH1 | |
| SCHEMBL2072467 | 0.61 | IMPDH2 (0.47) | NOS3NOS1NOS2LOXL2IMPDH2 | |
| SCHEMBL11518261 | 0.61 | CYP2A6 (0.47) | CYP2A6NOS3NOS1NOS2ALDH1A1 | |
| SCHEMBL16289106 | 0.61 | G6PD (0.33) | CYP2A6LOXL2IMPDH2IMPDH1CA2 | |
| SCHEMBL644338 | 0.61 | CA1 (0.44) | CYP2A6LOXL2IMPDH2IMPDH1CA2 | |
| SCHEMBL18440637 | 0.61 | CYP2A6 (0.47) | CYP2A6NOS3NOS1NOS2PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2952096-B1 | Amide compound, an arthropod pest control agent and a method for controlling arthropod pest | SUMITOMO CHEMICAL CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9814235-B2 | Method for controlling arthropod pest | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2017-11-14 | — | — | US | disclosed |
| EP-2952096-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | Sumitomo Chemical Company, Limited (JP) | 2015-12-09 | — | — | EP | disclosed |
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-12-03 | — | — | US | disclosed |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2015-01-01 | — | — | US | disclosed |
| EP-2813492-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | Sumitomo Chemical Co., Ltd (JP) | 2014-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344466-A1 | METHOD FOR CONTROLLING ARTHROPOD PEST | H1-0, H1-3, H1-2 | CYP2A6 961/4885NOS3 91/4885NOS1 309/4885 |
| US-20150005348-A1 | AMIDE COMPOUND AND USE THEREOF FOR PEST CONTROL | RPS8, MT-CO2, ARG1 | CYP2A6 812/4885NOS3 153/4885NOS1 263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.